Maze Therapeutics (MAZE) Common Equity (2024 - 2026)

Maze Therapeutics has disclosed Common Equity across 3 years of filings, most recently posting $341.7 million for Q1 2026.

• Common Equity for Q1 2026 came in at $341.7 million, up 16.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $341.7 million (up 16.99% YoY), and the FY2025 annual result was $355.0 million, up 214.07% from the prior year.
• Common Equity came in at $341.7 million for Q1 2026 at Maze Therapeutics, down from $355.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $379.4 million in Q3 2025 to a low of -$403.7 million in Q1 2024.
• The 3-year median for Common Equity is $262.2 million (2025), against an average of $41.0 million.
• Across the five-year window, Common Equity soared 233.35% in 2025 and gained 16.99% in 2026, its largest moves.
• Maze Therapeutics' Common Equity stood at -$311.2 million in 2024, then jumped by 214.07% to $355.0 million in 2025, then declined by 3.74% to $341.7 million in 2026.
• The last three Common Equity figures came in at $341.7 million (Q1 2026), $355.0 million (Q4 2025), and $379.4 million (Q3 2025), per Business Quant data.